Published research
The Eyerising Myopia Management Device has been validated by an extensive clinical trial program, with numerous peer-reviewed publications in leading journals demonstrating its efficacy and safety in the treatment of myopia. Below, you can find summaries of our key clinical papers. As new literature is constantly being published on repeated low-level red-light therapy, we also offer updates regarding new pertinent articles on our News page. For any other enquiries on our clinical evidence, ongoing and future research, please contact info@eyerisinginternational.com.
The Eyerising Myopia Management Device has been validated by an extensive clinical trial program, with many research publications from leading ophthalmology and optometry journals.
In particular, our landmark trial demonstrated that higher treatment compliance leads to higher treatment effect, with up to 87.7% efficacy in controlling myopia where children were >75% compliant with the treatment protocol.
We encourage you to speak to your eye care professional to discuss further the scientific literature underpinning repeated low-level red-light therapy. Should they have any further questions, please direct them to info@eyerisinginternational.com.
View our most important scientific papers
Ongoing research
We have ongoing clinical trials and real-world studies in Melbourne (Australia), Tokyo (Japan), San Francisco (USA), Madrid (Spain) and pan-Europe (France, Germany, Italy, Spain, Poland, Norway, Portugal). Our studies in San Francisco (USA), Paris (France), Porto (Portugal), Olzstyn (Poland) and Oslo (Norway) are presently recruiting.
To find out more, please contact info@eyerisinginternational.com.
We also have 5 ongoing clinical trials and real-world studies outside of China. These include randomised controlled trials at the Australian College of Optometry (Australia) on multi-ethnic efficacy, Tokyo Medical and Dental University (Japan) on high myopia in children and choroidal thickening in adults, University of California San Francisco (USA) on multi-ethnic efficacy, and Centro De Miopia Fernandez Velazquez (Spain) on adjunct use of RLRL with orthokeratology. Additionally, our Europe real-world study is involving participants across 7 European countries to examine the efficacy of RLRL in Caucasian populations.
Promising interim results are also available from our Australian, Japanese and Spanish trials. For more information, please contact info@eyerisinginternational.com. We look forward to the publication of both full manuscripts in due course.
Future research
At Eyerising International, we recognise how pivotal clinical research is to our story and greatly value our research collaborations. We welcome all external suggestions of investigator-initiated protocols, as well as joint research ventures.
Should you or your colleagues be interested in working with us, please contact info@eyerisinginternational.com to be put in contact with our clinical team.
